Microsoft word - final press release nextpharma gottingen alu alu (2).doc
NextPharma Technologies Doubles Alu Alu Packaging Capacity at its Göttingen Cephalosporins Facility
Surrey, UK, 28th January 2009 - NextPharma Technologies, a leading provider of
pharmaceutical product development, contract manufacturing, cold chain and
distribution outsourcing services, is pleased to announce that its Cephalosporins site
in Göttingen, Germany has doubled its Alu Alu packaging capacity.
In response to increased demand for Alu Alu blister business NextPharma has
increased its Cephalosporin packaging capacity to 18 million blisters per year - with
the installation of a second flexible Alu/Alu blister-line which can also produce
Alu/PVC/PVDC-blisters. This new machine provides currently nine different blisters
Alu/Alu and Alu/PVC blisters sizes and 54 different blister formats, it also benefits
from having the newest control units and a data matrix station for printing and saving
Dr Hermann Osterwald, Managing Director, Contract Manufacturing Services,
NextPharma Technologies commented “This new machine which was installed at the
end of last year will work well along side our existing Alu Alu blister line maximising
packaging capacity and flexibility for our customers. Bill Wedlake, CEO,
Nextpharma Technologies added – we’re aware of the rising requirement for this
packaging technology and are pleased to be in a position to meet market demands’.
NextPharma develops, manufactures, packages, and distributes a broad range of
products and formulations for its customers including solids, liquids and semi-solid
dosage forms, antibiotics, hormones and controlled release medicines. It has an
established leadership position in the high technology area of injectables
manufacturing (lyophilized and liquid fill), with particular expertise in product
development and manufacture of oncology medicines.
Contact:
Head Office: NextPharma Technologies, Ground Floor, Connaught House, Portsmouth Road, Send, Surrey, GU23 7JY, UK.
Bill Wedlake
Chief Executive Officer NextPharma Technologies Holding Limited Tel +44 (0) 1483 479 121 Notes to Editors: About NextPharma NextPharma Technologies, headquartered in the UK and founded in 2000, is a world class outsourcing partner to the pharmaceutical and biotechnology industry. We offer a full range of services from early phase product development, through clinical trial packaging to high volume commercial manufacturing. We are a world leader in lyophilization, sterile fill finish and pellet technologies and in specialist product manufacturing including cytotoxics, hormones, penicillins, cephalosporins and narcotics. Our sterile development and production offers a full range of drug delivery technologies including pre-filled syringes, vials and ampoules. We operate globally with seven product development centres, seven manufacturing plants and six temperature controlled storage and distribution sites across Europe and North America, supplying customers in North America, Europe and Japan. . We have 1,200 employees dedicated to serving over 200 customers world wide and a customer base, which includes many of the world’s leading pharmaceutical, specialty pharma and biotech companies We have a proven track record in almost all pharmaceutical technologies and product forms and in addition to the specialist areas above have capabilities in solids, semi- solids, liquids, sprays and dry dosage form technologies. All of our sites are either FDA inspected, in the process of upgrade for inspection or targeted for upgrade for inspection.
12th Night a Huge Success! To all who made 12th Night such a success, From the 12th Night Autocrat The purpose of this letter is to thank the MANY people who helped Aelfgifa and I received numerous compliments on hall, theduring 12th Night. Even late Saturday night, the weary were stilldecorations, the days activities and, of course, the feast. Very fewsmiling and felt good about
Bloomberg Brief | Bankruptcy & Restructuring BANKRUPTCY & RESTRUCTURING NEWS ROUNDUP European CLOs Riskier Without turn increase credit risk and hedging costs,” ADVANCE SHEETS More Loan Issuance: Moody’s Moody’s analysts led by London-based Dimitri Kaltsas , wrote in a report yesterday. Case Tests Constitutional rope will become riskier if their growth is Po
NextPharma Technologies Doubles Alu Alu Packaging Capacity at its